Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Gen Radionuclide Drug Conjugates December 30, 2025
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly December 30, 2025
Oncodesign Precision Medicine and Navigo Proteins announce the end of their collaboration in the development of radiotheranostics December 30, 2025
Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73 December 30, 2025
Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial of bexmarilimab + zimberelimab December 30, 2025
Athira Pharma Announces Exclusive License to Lasofoxifene Ph 3 Development Program for Metastatic Breast Cancer Candidate and Financing for up to $236M December 30, 2025
LIXTE Biotechnology, The University of Texas MD Anderson Cancer Center, and GSK expand collaboration on LB-100 to treat ovarian clear cell cancer December 30, 2025
GMP Manufacturing of AKTX-101 ADC Program Initiated to Support Ph 1 First-in-Human Clinical Trial December 30, 2025
Pidnarulex (CX-5461) – Enhertu combo to be evaluated in Ph 1b trial in HER2-positive and HER2-low solid tumors and breast cancer patients December 30, 2025
First Patient Dosed in Ph 3 ALPACCA Trial of Firmonertinib in 1L EGFR PACC Mutant NSCLC December 30, 2025
Enrollment progress update provided on Ph 3 TERZO study of COPIKTRA (duvelisib) in adults with R/R nodal TFHL December 30, 2025
First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland Announced December 30, 2025
Update Provided on Pivotal Ph 3 REGAL Trial of Galinpepimut-S (GPS) in AML; no outcome analyses performed December 30, 2025
FAILED TRIAL: LATIFY Ph 3 trial of ceralasertib + Imfinzi did not meet the OS primary endpoint vs SOC docetaxel in NSCLC patients December 30, 2025
12-Month OS Data from Ph 2a Trial of Atebimetinib + mGnP in 1L Pancreatic Cancer Patients to be announced on Jan 7, 2026 December 30, 2025
NDA for savolitinib for locally advanced/metastatic GC/GEJ adenocarcinoma patients with MET amplification accepted and granted priority review by the China NMPA December 30, 2025
Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer December 30, 2025
Positive Scientific Advice from EMA on the Design of a Ph 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Announced December 30, 2025
Japan’s MHLW approves Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with 2L+ FL December 30, 2025
First pancreatic cancer patient in global Ph 3 registrational trial, MAPKeeper 301, to be dosed in mid-2026 December 30, 2025
